A Phase 3 interventional study of Vadadustat and Darbepoetin alfa in Anemia, sponsored by Akebia Therapeutics. Completed at 59 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-22.
Sponsored by Akebia Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.
Among the 27 studies testing vadadustat in Anemia, this one is the 8th largest by enrollment, is the only one that started in 2020, is one of 14 in phase 3, and was the 22nd registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:
Mackay Memorial Hospital
Ages 18+
vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2020.
This study's enrollment of 319 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 60 across the 27 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 27 have an industry lead sponsor. The 4 most frequent:
Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.
23 studies in Anemia by Akebia Therapeutics: none open now, none under way, none of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 23 studies in Anemia by Akebia Therapeutics, this one is the 6th largest by enrollment, is the only one that started in 2020, is one of 10 in phase 3, and was the 20th registered.
Akebia Therapeutics’s Anemia studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing vadadustat in Anemia, from their registry updates:
Among Akebia Therapeutics’s 23 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will be conducted to demonstrate the efficacy and safety of vadadustat compared to darbepoetin alfa for the maintenance treatment of anemia in hemodialysis participants after conversion from current erythropoiesis-stimulating agent (ESA) therapy.
This study consists of three periods:
Individual participants will participate in total trial duration of approximately 64 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Two (Hb) values, at least 4 days apart, measured by the central laboratory during Screening within the following prespecified ranges:
Exclusion Criteria:
Participants meeting cut-off of the following equivalent mean weekly doses calculated over 8 weeks prior to Screening Visit 2
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vadadustat
Drug: Vadadustat
Drug: Darbepoetin alfa
oral tablets
intravenous or subcutaneous solution
Change From Baseline in Hb to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)
The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the PEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 20 through 26, regardless of intercurrent events. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as PEP value minus the Baseline value.
Time frame: Baseline; Weeks 20 to 26
Change From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52)
The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the SEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 46 through 52, regardless of intercurrent events. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as SEP value minus the Baseline value.
Time frame: Baseline; Weeks 46 to 52
This was a randomized, open-label, active-controlled study of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in hemodialysis participants, after conversion from erythropoiesis-stimulating agent (ESA therapy).
| Milestone | Vadadustat QD | Vadadustat TIW | Darbepoetin Alfa |
|---|---|---|---|
| Started | 105 | 106 | 108 |
| Completed | 54 | 50 | 67 |
| Not completed | 51 | 56 | 41 |
| Withdrew: Adverse event (includes death) | 14 | 19 | 10 |
| Withdrew: Physician decision | 4 | 2 | 1 |
| Withdrew: Withdrawal by subject | 7 | 6 | 2 |
| Withdrew: Lack of efficacy | 3 | 3 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 |
| Withdrew: Receipt of a solid organ, hematopoietic stem cell, or bone marrow transplantation | 0 | 2 | 3 |
| Withdrew: Meeting criteria for trial medication stopping rules | 16 | 20 | 19 |
| Withdrew: Change in dialysis modality | 0 | 1 | 2 |
| Withdrew: Permanent change in frequency of in-center hemodialysis from tiw | 1 | 0 | 0 |
| Withdrew: Other | 5 | 3 | 2 |
The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the PEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 20 through 26, regardless of intercurrent events. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as PEP value minus the Baseline value.
| Grams per deciliter (g/dL) | Vadadustat QD | Vadadustat TIW | Darbepoetin Alfa |
|---|---|---|---|
| Change From Baseline in Hb to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26) | 0.07 ± 0.12 | -0.19 ± 0.12 | 0.34 ± 0.12 |
The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the SEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 46 through 52, regardless of intercurrent events. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as SEP value minus the Baseline value.
| g/dL | Vadadustat QD | Vadadustat TIW | Darbepoetin Alfa |
|---|---|---|---|
| Change From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52) | 0.04 ± 0.15 | 0.03 ± 0.15 | 0.44 ± 0.15 |
Collected over From first dose of study drug (Day 1) up to Week 56 (from first dose of study drug to last dose + 4 weeks of follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vadadustat QD | 12/105 (11.4%) | 47/105 (44.8%) | 46/105 (43.8%) |
| Vadadustat TIW | 9/104 (8.7%) | 47/104 (45.2%) | 49/104 (47.1%) |
| Darbepoetin Alfa | 7/108 (6.5%) | 47/108 (43.5%) | 46/108 (42.6%) |
| Event | Vadadustat QD | Vadadustat TIW | Darbepoetin Alfa |
|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 7/105 | 8/104 | 4/108 |
| Acute myocardial infarctionCardiac disorders | 2/105 | 6/104 | 0/108 |
| AnaemiaBlood and lymphatic system disorders | 3/105 | 5/104 | 5/108 |
| HypervolaemiaMetabolism and nutrition disorders | 2/105 | 4/104 | 4/108 |
| COVID-19Infections and infestations | 2/105 | 2/104 | 4/108 |
| Myocardial infarctionCardiac disorders | 0/105 | 3/104 | 1/108 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/105 | 3/104 | 0/108 |
| PneumoniaInfections and infestations | 2/105 | 3/104 | 1/108 |
| SepsisInfections and infestations | 1/105 | 3/104 | 3/108 |
| Non-cardiac chest painGeneral disorders | 3/105 | 1/104 | 0/108 |
| Event | Vadadustat QD | Vadadustat TIW | Darbepoetin Alfa |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/105 | 15/104 | 6/108 |
| NauseaGastrointestinal disorders | 12/105 | 6/104 | 6/108 |
| COVID-19Infections and infestations | 12/105 | 11/104 | 10/108 |
| HypertensionVascular disorders | 6/105 | 11/104 | 10/108 |
| VomitingGastrointestinal disorders | 10/105 | 4/104 | 6/108 |
| FallInjury, poisoning and procedural complications | 10/105 | 6/104 | 5/108 |
| HyperkalaemiaMetabolism and nutrition disorders | 4/105 | 5/104 | 9/108 |
| Abdominal painGastrointestinal disorders | 4/105 | 4/104 | 8/108 |
| AnaemiaBlood and lymphatic system disorders | 5/105 | 7/104 | 7/108 |
| Back painMusculoskeletal and connective tissue disorders | 2/105 | 6/104 | 2/108 |
Randomized Population is defined as all participants randomized.
| Age, Continuous(years) | Vadadustat QD | Vadadustat TIW | Darbepoetin Alfa | Total |
|---|---|---|---|---|
| Mean | 60.9 ± 13.4 | 61.2 ± 12.5 | 60.8 ± 12.8 | 61.0 ± 12.9 |
| Sex: Female, Male(Participants) | Vadadustat QD | Vadadustat TIW | Darbepoetin Alfa | Total |
|---|---|---|---|---|
| Female | 47 | 46 | 43 | 136 |
| Male | 58 | 60 | 65 | 183 |
| Ethnicity (NIH/OMB)(Participants) | Vadadustat QD | Vadadustat TIW | Darbepoetin Alfa | Total |
|---|---|---|---|---|
| Hispanic or Latino | 23 | 36 | 26 | 85 |
| Not Hispanic or Latino | 82 | 70 | 82 | 234 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Vadadustat QD | Vadadustat TIW | Darbepoetin Alfa | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 0 | 3 |
| Asian | 4 | 1 | 3 | 8 |
| Black Or African American | 31 | 30 | 33 | 94 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 1 | 3 |
| White | 68 | 67 | 71 | 206 |
| Not Reported | 1 | 3 | 0 | 4 |
| Reported as Other | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2020 to primary completion in Nov 2021, 17 months.
Results were first posted in May 2025, 3 years 5 months after primary completion. A results delay was requested in Nov 2022.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 17 months is below that.
Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vadadustat